tiprankstipranks
Advertisement
Advertisement

MXCT Stock Latest News

MaxCyte reports Q2 EPS (8c), consensus (9c)
The FlyMaxCyte reports Q2 EPS (8c), consensus (9c)
5d ago
MXCT
MaxCyte (MXCT) Earnings Call Signals Stabilizing Turnaround
PremiumCompany Announcements
MaxCyte (MXCT) Earnings Call Signals Stabilizing Turnaround
10d ago
MXCT
MaxCyte Reports Q2 Results, Highlights Genentech Partnership
PremiumCompany Announcements
MaxCyte Reports Q2 Results, Highlights Genentech Partnership
10d ago
8K
MXCT
MaxCyte enters technology license partnership with Genentech
PremiumThe Fly
MaxCyte enters technology license partnership with Genentech
1M ago
CHRO
MXCT
MaxCyte Shareholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
MaxCyte Shareholders Reelect Directors and Ratify Auditor
2M ago
8K
MXCT
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery
PremiumCompany AnnouncementsMaxCyte Regains Nasdaq Compliance After Bid Price Recovery
2M ago
8K
MXCT
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
Premium
Company Announcements
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
3M ago
MXCT
MaxCyte reports Q1 EPS (4c), consensus (9c)
Premium
The Fly
MaxCyte reports Q1 EPS (4c), consensus (9c)
3M ago
MXCT
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
PremiumThe Fly
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
3M ago
MXCT
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
PremiumCompany Announcements
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
3M ago
8K
MXCT
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
PremiumRatings
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
5M ago
MXCT
MaxCyte Appoints New Chief Financial Officer Ahuja
PremiumCompany Announcements
MaxCyte Appoints New Chief Financial Officer Ahuja
5M ago
8K
MXCT
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
PremiumCompany AnnouncementsMaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
5M ago
MXCT
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
Premium
Company Announcements
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
5M ago
MXCT
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
Premium
The Fly
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
5M ago
MXCT
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
PremiumCompany Announcements
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
5M ago
8K
MXCT
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
PremiumThe Fly
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
5M ago
MXCT
MaxCyte reports Q4 EPS (9c), consensus (8c)
PremiumThe Fly
MaxCyte reports Q4 EPS (9c), consensus (8c)
5M ago
MXCT
MaxCyte appoints Parmeet Ahuja as CFO
PremiumThe Fly
MaxCyte appoints Parmeet Ahuja as CFO
5M ago
A
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
PremiumCompany AnnouncementsMaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
5M ago
8K
MXCT
MaxCyte announced the launch of ExPERT DTx
Premium
The Fly
MaxCyte announced the launch of ExPERT DTx
6M ago
MXCT
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
Premium
The Fly
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
7M ago
MXCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >